Drybench Patent.
ESTRADIOL, NDA 203752
The patents and exclusivities FDA's Orange Book lists for NDA 203752 as captured on 14 October 2026, each date named by its rule and its rows, and the rows of FDA's Paragraph IV list that give this NDA's number, as captured on 17 October 2026. Listed protection is a range of dates, never one date.
FDA capture · review pending. Each row is shown as captured from FDA's Orange Book files and Paragraph IV list. Dates are FDA's own; spreadsheet day numbers are shown as dates, and a cell that cannot be read as one date is shown as written and left out of the range. Where FDA lists a *PED row without flags, its flags are read from the base row and marked so. A Paragraph IV row is placed here only by the number in its RLD/NDA cell; nothing is joined by name. How this page reads FDA's files has not been independently reviewed by a regulatory-affairs reviewer.
- Orange Book captured
- 14 October 2026
- Paragraph IV list captured
- 17 October 2026
- Last checked
- 30 October 2026
- Data-branch commit
- dadcab56563716abea6c5e31a5e1970080c778ef
Listed protection is a range of the dates FDA lists, not a forecast of market entry, and not legal, regulatory or investment advice.
Dates as listed in FDA's Orange Book capture of 14 October 2026. This page does not say whether a date has passed; compare it with today's date and FDA's current Orange Book. This page shows only what the capture of 14 October 2026 lists. It does not show patents or exclusivities listed before and since removed.
Listed protection
Listed dates run from 10 Jul 2028 to 4 Jul 2030, each by its own rule; no one date stands for this product.
- Earliest listed date
- 10 Jul 2028US 9,724,310, substance and product patentRule R1 · Product 005 · patent.txt line 4,138
- Latest listed date
- 4 Jul 2030US 8,231,906, substance and product patentRule R1 · Products 001, 002, 003, 004, 005 · patent.txt lines 4,125, 4,128, 4,131, 4,134, 4,137
- Latest substance patent
- 4 Jul 2030US 8,231,906, substance and product patentRule R1 · Products 001, 002, 003, 004, 005 · patent.txt lines 4,125, 4,128, 4,131, 4,134, 4,137
- Latest listed patent
- 4 Jul 2030US 8,231,906, substance and product patentRule R1 · Products 001, 002, 003, 004, 005 · patent.txt lines 4,125, 4,128, 4,131, 4,134, 4,137
- Latest exclusivity
- None listed
5 use-code patents, blocking the coded use only
Products
Each product number FDA lists under NDA 203752, as listed. The sections below name products by these numbers.
Product 001 · MINIVELLE
- Dosage form; route
- FILM, EXTENDED RELEASE;TRANSDERMAL
- Strength
- 0.0375MG/24HR
- Approval date as listed
- 29 Oct 2012
- Type as listed
- RX
- Applicant as listed
- NOVEN PHARMACEUTICALS INC
Product 002 · MINIVELLE
- Dosage form; route
- FILM, EXTENDED RELEASE;TRANSDERMAL
- Strength
- 0.075MG/24HR
- Approval date as listed
- 29 Oct 2012
- Type as listed
- RX
- Applicant as listed
- NOVEN PHARMACEUTICALS INC
Product 003 · MINIVELLE
- Dosage form; route
- FILM, EXTENDED RELEASE;TRANSDERMAL
- Strength
- 0.05MG/24HR
- Approval date as listed
- 29 Oct 2012
- Type as listed
- RX
- Applicant as listed
- NOVEN PHARMACEUTICALS INC
Product 004 · MINIVELLE
- Dosage form; route
- FILM, EXTENDED RELEASE;TRANSDERMAL
- Strength
- 0.1MG/24HR
- Approval date as listed
- 29 Oct 2012
- Type as listed
- RX
- Applicant as listed
- NOVEN PHARMACEUTICALS INC
Product 005 · MINIVELLE
- Dosage form; route
- FILM, EXTENDED RELEASE;TRANSDERMAL
- Strength
- 0.025MG/24HR
- Approval date as listed
- 23 Sep 2014
- Type as listed
- RX
- Applicant as listed
- NOVEN PHARMACEUTICALS INC
Listed patents
Every patent the FDA lists for this product, as the application holder submitted it, with its flags. The FDA does not verify listings.
5 entries from 16 rows as listed; rows merge only where every cell shown is the same, each with its product numbers.
US 9,724,310, substance and product patent
patent.txt line 4,138- Expiry as listed
- 10 Jul 2028
- Rule
- R1
- Flags
- substance · product
- Product numbers
- 005
US 9,730,900, use patent
patent.txt lines 4,126, 4,129, 4,132, 4,135- Expiry as listed
- 10 Jul 2028
- Rule
- R1
- Flags
- use code U-2086
- Product numbers
- 001, 002, 003, 004
US 9,730,900, product and use patent
patent.txt line 4,139- Expiry as listed
- 10 Jul 2028
- Rule
- R1
- Flags
- product · use code U-2086
- Product numbers
- 005
US 9,833,419, product patent
patent.txt lines 4,127, 4,130, 4,133, 4,136, 4,140- Expiry as listed
- 10 Jul 2028
- Rule
- R1
- Flags
- product
- Product numbers
- 001, 002, 003, 004, 005
US 8,231,906, substance and product patent
patent.txt lines 4,125, 4,128, 4,131, 4,134, 4,137- Expiry as listed
- 4 Jul 2030
- Rule
- R1
- Flags
- substance · product
- Product numbers
- 001, 002, 003, 004, 005
Listed exclusivities
Each exclusivity FDA lists for NDA 203752, with its code, FDA's definition of the code where the store's code list gives one, and its date as listed.
The Orange Book capture of 14 October 2026 lists no exclusivity for NDA 203752.
Paragraph IV list rows giving NDA 203752
The rows of FDA's Paragraph IV certifications list as captured on 17 October 2026 whose RLD/NDA cell gives NDA 203752, each cell as listed.
FDA's Paragraph IV list names no patent number, so it does not say which of the patents on this page an applicant certified against.
The list gives the last qualifying patent's expiry without pediatric exclusivity; in the app's Patents view, the Orange Book lists any *PED period as a separate row with its own date. The two dates describe different things. A blank cell is one FDA left blank in its list. Dates are FDA's own; the last qualifying patent expiry is not recomputed from the Orange Book.
Rows whose RLD/NDA cell we could not read as exactly one NDA number are kept apart on the list page; some may concern this product.
Rows on FDA's Paragraph IV list whose RLD/NDA cell gives NDA 203752
Estradiol · Transdermal System · 0.025 mg/day
RLD/NDA as listed: Minivelle 203752- First PIV submission
- 8 May 2015
- ANDAs
- 1
- 180-day status
- Deferred
- Decision posted
- 8 Oct 2019
- First applicant approval
- 15 Aug 2018
- First marketing
- 1 Nov 2018
- Last qualifying patent expiry (as listed by FDA)
- 4 Jul 2030
Estradiol · Transdermal System · 0.0375 mg/day 0.05 mg/day 0.075 mg/day 0.1 mg/day
RLD/NDA as listed: Minivelle 203752- First PIV submission
- 18 Aug 2014
- ANDAs
- 1
- 180-day status
- Deferred
- Decision posted
- 8 Oct 2019
- First applicant approval
- 15 Aug 2018
- First marketing
- 1 Nov 2018
- Last qualifying patent expiry (as listed by FDA)
- 4 Jul 2030
Notes from the trace
- R6 tentative approvals: not in the Orange Book data files as captured; the Drugs@FDA join is a later ruling.
Patents vs FDA exclusivityHow to read the Orange Book data filesParagraph IV certificationWhat changed, by week